Press release
Chronic Hepatitis B Virus Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Hepatitis B Virus pipeline constitutes 50+ key companies continuously working towards developing 55+ Chronic Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Chronic Hepatitis B Virus Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.
The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years.
*
Chronic Hepatitis B Virus companies working in the treatment market are Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others, are developing therapies for the Chronic Hepatitis B Virus treatment
*
Emerging Chronic Hepatitis B Virus therapies in the different phases of clinical trials are- AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFN, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.
*
In June 2025, TherVacB, an innovative therapeutic vaccine for chronic hepatitis B developed by Helmholtz Munich in partnership with the German Center for Infection Research (DZIF), began its first clinical trial in patients. After a successful Phase Ia trial in healthy volunteers, which showed a favorable safety profile and induced the intended immune responses, the study has advanced to a multi-center Phase Ib/IIa trial, with the first patient enrolled in June 2025.
*
In May 2025, interim data from a Phase 2b clinical trial showed that AHB-137, Ausperbio's investigational therapy, safely and effectively suppressed the hepatitis B virus (HBV) in individuals with chronic hepatitis B. These encouraging results, consistent with earlier findings from an ongoing Phase 1/2a trial (NCT06115993), were presented during a poster session at the annual European Association for the Study of the Liver Congress.
*
In May 2025, Vir Biotechnology's combination therapy aimed at a "functional cure" for hepatitis B did not meet efficacy endpoints in a Phase II trial. Data from the 24-week mark of the ongoing MARCH Phase II study (NCT04856085) showed that only 17% (3/18) of patients receiving tobevibart and elebsiran alone, and 21% (3/14) of those receiving the combination with peginterferon, achieved undetectable hepatitis B surface antigen (HBsAg) among patients with baseline HBsAg
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma here
News-ID: 4162421 • Views: …
More Releases from ABNewswire

Rhino Rescue's Quality Pledge: Unveiling the Extreme Resilience of Core Componen …
Discover Rhino Rescue's quality pledge through our extreme component testing. See why our tactical gear is built to perform.
Our Commitment and Responsibility
In the life and death arena of emergency response, where seconds matter, the dependability of your equipment is absolute. It is a fact that has been guiding our mission since our parent company, Nanchi Medical, was established in 2010. Having a 14-year history in the first aid industry and…

Tampa SEO Launches Cutting-Edge Local Search Optimization Services to Help Tampa …
Tampa SEO, a full-service digital marketing agency based in Tampa Bay, today announced the official launch of its enhanced SEO and digital marketing services at http://tampa-seo.net. The company specializes in helping local businesses increase their online visibility, generate qualified leads, and outperform competitors through data-driven, ethical search engine optimization strategies.
Helping Local Businesses Thrive in the Digital Age
With nearly 97% of consumers searching online for local services before making a purchase,…

Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveIn …
The Key Fibromyalgia Companies in the market include - Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, UCB Pharma, Pierre Fabre Medicament, UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial - Portela C S.A, and others.
DelveInsight's "Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States,…

DMB Plumbing & Heating Urges Homeowners to Schedule Pre-Winter Heating Inspectio …
DMB Plumbing & Heating Inc. of Bridgewater, led by Dean Blanchard, is urging homeowners to schedule pre-winter heating inspections.
As temperatures in Massachusetts begin to dip and residents prepare their homes for another New England winter, DMB Plumbing & Heating Inc., a locally owned and operated company based in Bridgewater, is reminding homeowners of the importance of pre-winter heating inspections.
Founded and operated by Dean Blanchard, DMB Plumbing & Heating has long…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…